Home>Topics>>Celgene And The Race To Cure Multiple Myeloma
Celgene And The Race To Cure Multiple Myeloma
Healthcare Sector and Stocks Analysis from Seeking Alpha
Fri, 15 Feb 2013
By Peter Geschek : Pomalyst In February the FDA approved Pomalyst (pomalidomide) developed by Celgene ( CELG ) for the treatment of patients with multiple myeloma whose disease progressed after being treated with other cancer drugs, like Celgene's Revlimid or Johnson & Johnson/Takeda's Velcade. ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.